Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas

European Journal of Endocrinology

Volumn 170, Issue 3, 2014, Pages 385-391

  Ragazzon, Bruno ^a,b,c   Libé, Rossella ^a,b,c,d,e   Assié, Guillaume ^a,b,c,d   Tissier, Frédérique ^a,b,c,d,f   Barreau, Olivia ^a,b,c,d   Houdayer, Claude ^c,g,h   Perlemoine, Karine ^a,b,c   Audebourg, Anne ^f   Clauser, Eric ^f   René Corail, Fernande ^a,b,c   Bertagna, Xavier ^a,b,c,d   Dousset, Bertrand ^f   Bertherat, Jérôme ^a,b,c,d   Groussin, Lionel ^a,b,c,d  

^a INSTITUT COCHIN   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e French COMETE Network for Adrenal Cancer   (France)

^f université Paris Cité   (France)

^g INSTITUT CURIE   (France)

^h INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DNA; JANUS KINASE 3; RETINOBLASTOMA PROTEIN;

ADRENAL CORTEX CARCINOMA; ALLELE; ARTICLE; BETA CATENIN GENE; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; DNA POLYMORPHISM; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE LOSS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; JAK3 GENE; MASSIVE PARALLEL SEQUENCING; MUTATION RATE; MUTATIONAL ANALYSIS; NONSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTO ONCOGENE; RB1 GENE; SEQUENCE ANALYSIS; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; BETA CATENIN; GENE EXPRESSION PROFILING; HUMANS; JANUS KINASE 3; MUTATION; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896296555     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0778     Document Type: Article

References (26)

1. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budaus L, Shariat SF, Guazzoni G, Montorsi F et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. European Journal of Cancer 2010 46 713-719. (doi:10.1016/j.ejca.2009.12.007)
2. de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, Rene-Corail F, Dousset B, Bertagna X, Clauser E & Bertherat J. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. Journal of Clinical Oncology 2009 27 1108-1115. (doi:10.1200/JCO.2008.18.5678)
3. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G & Hammer G. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clinical Cancer Research 2009 15 668-676. (doi:10.1158/1078-0432.CCR-08-1067)
4. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Research 2001 61 6762-6767. (Pubitemid 32896498)
5. Libe R, Groussin L, Tissier F, Elie C, Rene-Corail F, Fratticci A, Jullian E, Beck-Peccoz P, Bertagna X, Gicquel C et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clinical Cancer Research 2007 13 844-850. (doi:10.1158/1078- 0432.CCR-06-2085)
6. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere AM, Rene-Corail F, Jullian E, Gicquel C, Bertagna X et al. Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Research 2005 65 7622-7627. (doi:10.1158/0008-5472.CAN-05-0593)
7. Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libe R, Chokri I, Audebourg A, Royer B, Sbiera S et al. β-Catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clinical Cancer Research 2011 17 328-336. (doi:10.1158/1078-0432.CCR-10-2006)
8. Ragazzon B, Libe R, Gaujoux S, Assie G, Fratticci A, Launay P, Clauser E, Bertagna X, Tissier F, de Reynies A et al. Transcriptome analysis reveals that p53 and {β}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Research 2010 70 8276-8281. (doi:10.1158/0008- 5472.CAN-10-2014)
9. Jurinke C, Oeth P & van den Boom D. MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA analysis. Molecular Biotechnology 2004 26 147-164. (doi:10.1385/MB:26:2:147)
10. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L et al. High-throughput oncogene mutation profiling in human cancer. Nature Genetics 2007 39 347-351. (doi:10.1038/ng1975)
11. Vivante A, Amariglio N, Koren-Michowitz M, Ashur-Fabian O, Nagler A, Rechavi G & Cohen Y. High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations. Leukemia 2007 21 1318-1321. (doi:10.1038/sj.leu.2404635)
12. Houdayer C, Gauthier-Villars M, Lauge A, Pages-Berhouet S, Dehainault C, Caux-Moncoutier V, Karczynski P, Tosi M, Doz F, Desjardins L et al. Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. Human Mutation 2004 23 193-202. (doi:10.1002/humu.10303)
13. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. Journal of Clinical Investigation 2010 120 4478-4492. (doi:10.1172/JCI44239)
14. Houdayer C, Dehainault C, Mattler C, Michaux D, Caux-Moncoutier V, Pages-Berhouet S, d'Enghien CD, Lauge A, Castera L, Gauthier-Villars M et al. Evaluation of in silico splice tools for decision-making in molecular diagnosis. HumanMutation 2008 29 975-982. (doi:10.1002/humu.20765)
15. Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, Bourdon V, BronnerM, BuissonM, Coulet F, Gaildrat P et al. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/ in vitro studies on BRCA1 and BRCA2 variants. Human Mutation 2012 33 1228-1238. (doi:10.1002/humu.22101)
16. Abidi O, Knari S, Sefri H, Charif M, Senechal A, Hamel C, Rouba H, Zaghloul K, El Kettani A, Lenaers G et al. Mutational analysis of the RB1 gene in Moroccan patients with retinoblastoma. Molecular Vision 2011 17 3541-3547.
17. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 2009 4 e7887. (doi:10.1371/journal.pone. 0007887)
18. Bremner R & Zacksenhaus E. Cyclins, Cdks, E2f, Skp2, and more at the first International RB Tumor Suppressor Meeting. Cancer Research 2010 70 6114-6118. (doi:10.1158/0008-5472.CAN-10-0358)
19. Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, Theriault BL, Prigoda-Lee NL, Spencer C, Dimaras H, Corson TW et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncology 2013 14 327-334. (doi:10.1016/S1470-2045(13)70045-7)
20. Sherr CJ & McCormick F. The RB, and p53 pathways in cancer. Cancer Cell 2002 2 103-112. (doi:10.1016/S1535-6108(02)00102-2)
21. Conkrite K, Sundby M, Mu D, Mukai S & MacPherson D. Cooperation between Rb and Arf in suppressing mouse retinoblastoma. Journal of Clinical Investigation 2012 122 1726-1733. (doi:10.1172/JCI61403)
22. Macleod KF. The RB, tumor suppressor: a gatekeeper to hormone independence in prostate cancer? Journal of Clinical Investigation 2010 120 4179-4182. (doi:10.1172/JCI45406)
23. Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nature Genetics 2012 44 1316-1320. (doi:10.1038/ng.2469)
24. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013 497 67-73. (doi:10.1038/nature12113)
25. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nature Genetics 2013 45 860-867. (doi:10.1038/ng.2699)
26. De Martino MC, Al Ghuzlan A, Aubert S, Assie G, Scoazec JY, Leboulleux S, Do Cao C, Libe R, Nozieres C, Lombes M et al. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism 2013 98 4080-4088. (doi:10.1210/jc.2013- 2165)